NewAmsterdam Pharma Company NV (NASDAQ:NAMS) shares, rose in value on Thursday, April 16, with the stock price up by 1.93% to the previous day’s close as strong demand from buyers drove the stock to $16.34.
Actively observing the price movement in the last trading, the stock closed the session at $16.03, falling within a range of $15.9962 and $16.585. The value of beta (5-year monthly) was -0.002. Referring to stock’s 52-week performance, its high was $27.29, and the low was $14.06. On the whole, NAMS has fluctuated by -30.79% over the past month.
With the market capitalization of NewAmsterdam Pharma Company NV currently standing at about $1.79 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-25.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 1.46M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that NAMS’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of NAMS currently trading nearly -11.83% and -18.79% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 35.87, while the 7-day volatility ratio is showing 7.76% which for the 30-day chart, stands at 8.58%. Furthermore, NewAmsterdam Pharma Company NV (NAMS)’s beta value is 0.15, and its average true range (ATR) is 1.43.
A comparison of NewAmsterdam Pharma Company NV (NAMS) with its peers suggests the former has fared considerably weaker in the market. NAMS showed an intraday change of 1.93% in last session, and over the past year, it shrunk by -16.21%%.
Data on historical trading for NewAmsterdam Pharma Company NV (NASDAQ:NAMS) indicates that the trading volumes over the past 10 days have averaged 1.05 and over the past 3 months, they’ve averaged 1.03 million. According to company’s latest data on outstanding shares, there are 108.06 million shares outstanding.
Nearly 44.40% of NewAmsterdam Pharma Company NV’s shares belong to company insiders and institutional investors own 48.09% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.34 million shares as on 2025-03-31, resulting in a short ratio of 4.14. According to the data, the short interest in NewAmsterdam Pharma Company NV (NAMS) stood at 732.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 3.04 million. The stock has fallen by -36.42% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NAMS stock heading into the next quarter.
